1. Home
  2. RYTM vs NSP Comparison

RYTM vs NSP Comparison

Compare RYTM & NSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • NSP
  • Stock Information
  • Founded
  • RYTM 2008
  • NSP 1986
  • Country
  • RYTM United States
  • NSP United States
  • Employees
  • RYTM N/A
  • NSP N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • NSP Professional Services
  • Sector
  • RYTM Health Care
  • NSP Consumer Discretionary
  • Exchange
  • RYTM Nasdaq
  • NSP Nasdaq
  • Market Cap
  • RYTM 3.1B
  • NSP 2.9B
  • IPO Year
  • RYTM 2017
  • NSP 1997
  • Fundamental
  • Price
  • RYTM $57.07
  • NSP $79.28
  • Analyst Decision
  • RYTM Strong Buy
  • NSP Hold
  • Analyst Count
  • RYTM 10
  • NSP 4
  • Target Price
  • RYTM $66.90
  • NSP $95.67
  • AVG Volume (30 Days)
  • RYTM 549.1K
  • NSP 391.8K
  • Earning Date
  • RYTM 02-20-2025
  • NSP 02-06-2025
  • Dividend Yield
  • RYTM N/A
  • NSP 2.99%
  • EPS Growth
  • RYTM N/A
  • NSP N/A
  • EPS
  • RYTM N/A
  • NSP 3.16
  • Revenue
  • RYTM $112,530,000.00
  • NSP $6,547,871,000.00
  • Revenue This Year
  • RYTM $63.77
  • NSP $2.24
  • Revenue Next Year
  • RYTM $44.91
  • NSP $5.31
  • P/E Ratio
  • RYTM N/A
  • NSP $25.40
  • Revenue Growth
  • RYTM 81.55
  • NSP 2.38
  • 52 Week Low
  • RYTM $35.17
  • NSP $71.69
  • 52 Week High
  • RYTM $68.58
  • NSP $117.48
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 52.43
  • NSP 55.97
  • Support Level
  • RYTM $52.71
  • NSP $76.60
  • Resistance Level
  • RYTM $60.12
  • NSP $80.89
  • Average True Range (ATR)
  • RYTM 2.11
  • NSP 2.44
  • MACD
  • RYTM -0.00
  • NSP 0.49
  • Stochastic Oscillator
  • RYTM 58.93
  • NSP 90.33

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

About NSP Insperity Inc.

Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.

Share on Social Networks: